항암화학요법을 받은 고형암 환자들의 중증 의료관련폐렴의 임상상
Severe Health-care Associated Pneumonia among the Solid Cancer Patients on Chemotherapy
0
조회
0
다운로드
0
인용
0
참고문헌
키워드
초록
Background: There are only inadequate studies on the characteristics of severe pneumonia in the patients who have solid cancer and who are treated with cytotoxic chemotherapy and also on the usefulness of the various severity index scores. Methods: We retrospectively reviewed 31 patients who were treated with cytotoxic chemotherapy because of solid cancer and who were admitted to the medical ICU at Samsung Medical Center from April 2007 to August 2008. Results: The median age of the 31 patients was 64 years old (34-79). The types of solid cancer were lung cancer (19, 61.3%), gastroesophageal cancer (4, 12.9%), breast cancer (2, 6.5%), liver cancer (1, 3.2%), ovarian cancer (1, 3.2%) and other types of cancer (4, 12.9%). The hospital mortality rate was 64.5%. We were able to determine the pathogen of 19 (61.3%) patients; S. pneumoniae (6), S. aureus (3), Candida species (3), P. aeruginosa (2), K. pneumoniae (1), Pneumocystis jiroveci (1) and others (3). There were no statistically differences of the laboratory data and severity index scores (PSI, CURB-65, APACHE II, SOFA, SAPS 3) between the survivors and non-survivors, except the P/F ratio. Conclusions: The hospital mortality rate of severe pneumonia in patients who had solid cancer and who received cytotoxic chemotherapy was high. The major pathogen was S. pneumoniae. The severity indexes for general pneumonia were not useful to these patients.
Abstract
Background: There are only inadequate studies on the characteristics of severe pneumonia in the patients who have solid cancer and who are treated with cytotoxic chemotherapy and also on the usefulness of the various severity index scores. Methods: We retrospectively reviewed 31 patients who were treated with cytotoxic chemotherapy because of solid cancer and who were admitted to the medical ICU at Samsung Medical Center from April 2007 to August 2008. Results: The median age of the 31 patients was 64 years old (34-79). The types of solid cancer were lung cancer (19, 61.3%), gastroesophageal cancer (4, 12.9%), breast cancer (2, 6.5%), liver cancer (1, 3.2%), ovarian cancer (1, 3.2%) and other types of cancer (4, 12.9%). The hospital mortality rate was 64.5%. We were able to determine the pathogen of 19 (61.3%) patients; S. pneumoniae (6), S. aureus (3), Candida species (3), P. aeruginosa (2), K. pneumoniae (1), Pneumocystis jiroveci (1) and others (3). There were no statistically differences of the laboratory data and severity index scores (PSI, CURB-65, APACHE II, SOFA, SAPS 3) between the survivors and non-survivors, except the P/F ratio. Conclusions: The hospital mortality rate of severe pneumonia in patients who had solid cancer and who received cytotoxic chemotherapy was high. The major pathogen was S. pneumoniae. The severity indexes for general pneumonia were not useful to these patients.
참고문헌 (15)
- Hughes WT, "2002 guidelines for the use of antimicrobial agents in neutropenic patients with cancer", Clin Infect Dis, 34, pp.730~751 (2002)
- Vento S, "Lung infections after cancer chemotherapy", Lancet Oncol, 9, pp.982~992 (2008)
- Carratalà J, "Outpatient care compared with hospitalization for community-acquired pneumonia: a randomized trial in low-risk patients", Ann Intern Med, 142, pp.165~172 (2005)
- Friedman ND, "Health care--associated bloodstream infections in adults: a reason to change the accepted definition of community-acquired infections", Ann Intern Med, 137, pp.791~797 (2002)
- McDonald JR, "Risk factors for ineffective therapy in patients with bloodstream infection", Arch Intern Med, 165, pp.308~313 (2005)
- Mandell LA, "Infectious Diseases Society of America", American Thoracic Society consensus guidelines on the management of community-acquired pneumonia in adults, 2007, pp.44(2), S27~S72
- 송재훈, "지역사회획득 폐렴의 치료지침 권고안", Infection and Chemotherapy, 41(3), pp.133~153 (2009), 대한감염학회
- American Thoracic Society, "Guidelines for the management of adults with hospital-acquired, ventilator-associated, and healthcare-associated pneumonia", Am J Respir Crit Care Med, 171, pp.388~416 (2005)
- Carratalà J, "Health care-associated pneumonia requiring hospital admission: epidemiology, antibiotic therapy, and clinical outcomes", Arch Intern Med, 167, pp.1393~1399 (2007)
- Shindo Y, "Health-care-associated pneumonia among hospitalized patients in a Japanese community hospital", Chest, 135, pp.633~640 (2009)
- Fine MJ, "A prediction rule to identify low-risk patients with community-acquired pneumonia", N Engl J Med, 336, pp.243~250 (1997)
- Micek ST, "Health care-associated pneumonia and community-acquired pneumonia: a single-center experience", Antimicrob Agents Chemother, 51, pp.3568~3573 (2007)
- Carratalà J, "What is healthcare-associated pneumonia and how is it managed?", Curr Opin Infect Dis, 21, pp.168~173 (2008)
- Lim WS, "Defining community acquired pneumonia severity on presentation to hospital: an international derivation and validation study", Thorax, 58, pp.377~382 (2003)
- British Thoracic Society Standards of Care Committee, "BTS guidelines for the management of community acquired pneumonia in adults", Thorax, 56(4), pp.IV1~IV64 (2001)